Ultrasound-Based Assessment of Preperitoneal Fat as a Surrogate Marker of Cardiovascular Risk: Comparative Study Between People Living with HIV and Controls.


Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 1 1 2022
medline: 22 3 2022
entrez: 31 12 2021
Statut: ppublish

Résumé

Optimal management of cardiovascular disease should start with the identification of subjects at subclinical stages. However, available tools are not always accurate or affordable. We assess the usefulness of ultrasound-guided measurement of abdominal fat layers as a surrogate marker of cardiovascular risk. We performed a cross-sectional, case-control, exploratory, pilot study in 10 people living with HIV (PLWH) and 10 HIV-uninfected subjects (control group) matched for age, sex, and body mass index. All participants were men 45-60 years of age, with no active disease or previous abdominal surgery; the PLWH group had been virologically suppressed for ≥2 years under stable antiretroviral therapy. The thickness of abdominal superficial and deep subcutaneous fat, preperitoneal fat, omental (periaortic) fat, and retroperitoneal (perirenal) fat was compared between both groups. Correlations between fat layers and traditional markers of cardiovascular risk were assessed. The thickness of most layers was always higher among PLWH. The differences were statistically significant for the preperitoneal fat layer (

Identifiants

pubmed: 34969253
doi: 10.1089/AID.2021.0141
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

222-227

Auteurs

Anna Bonjoch (A)

Lluita Contra la SIDA Foundation, Infectious Diseases Service, HIV Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Francisco de Cabo (F)

Instituts Guirado, Endocrinology Department, Barcelona, Spain.
Endocrinology Department, Clínica Sagrada Familia, Barcelona, Spain.

Jordi Puig (J)

Lluita Contra la SIDA Foundation, Infectious Diseases Service, HIV Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Núria Perez-Alvarez (N)

Lluita Contra la SIDA Foundation, Infectious Diseases Service, HIV Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.
Statistics and Operational Research Department, Technical University of Catalonia, Barcelona, Catalonia, Spain.

Patricia Echeverria (P)

Lluita Contra la SIDA Foundation, Infectious Diseases Service, HIV Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Bonaventura Clotet (B)

Lluita Contra la SIDA Foundation, Infectious Diseases Service, HIV Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.
Infectious Diseases and Immunity, Centre for Health and Social Care Research (CESS), Medicine Department, School of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Catalonia, Spain.
AIDS Research Institute-IrsiCaixa, Basic Investigation in HIV Department, Germans Trias i Pujol Research Institute-IGTP, Hospital Universitari Germans Trias i Pujol, Barcelona, Catalonia, Spain.

Guillem Cuatrecasas (G)

Endocrinology Department, Clínica Sagrada Familia, Barcelona, Spain.
School of Health Sciences, Medicine Department, Universitat Oberta Catalunya, Barcelona, Spain.

Eugènia Negredo (E)

Lluita Contra la SIDA Foundation, Infectious Diseases Service, HIV Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.
Infectious Diseases and Immunity, Centre for Health and Social Care Research (CESS), Medicine Department, School of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH